Trial Profile
Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEXIS
- 07 Dec 2022 Planned End Date changed from 1 Jun 2022 to 21 Jun 2037.
- 07 Dec 2022 Planned primary completion date changed from 1 Jun 2022 to 21 Jun 2032.
- 07 Dec 2022 Status changed from completed to active, no longer recruiting.